This week, we will discuss the 2024 KDIGO Guidelines on CKD, part 1. In this section we will discuss the first two chapters on CKD evaluation and risk stratification. Let’s dive in!
This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.
This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.
This week we discuss the BICAR-ICU trial from France. In patients who are critically ill with metabolic acidosis, does giving bicarb help improve survival? More importantly, does it help with kidney outcomes? Join us to discuss
There is a theory that inducing metabolic acidosis in vented COPD patients will stimulate respiration and help them get off the ventilator. The DIABLO trial is an RCT which looks at this theory.